Standard treatment for both types of hemophilia involves replacement therapy, in which a version of the deficient clotting ...

Researchers reviewed data from 14 hemophilia patients treated with Sevenfact to better understand its real-world safety and ...

As many as 30% of people living with severe hemophilia A develop inhibitors such as TFPI, which can be produced by the body’s immune response to clotting factors in replacement therapy, often limiting ...

After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...

The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for ...

Be Biopharma, Inc. ("Be Bio" or "the Company"), a leader in the discovery and development of engineered B Cell Medicines (BCMs), today announced key milestones alongside a new round of funding as its ...

Novo Nordisk's Alhemo drug has been recommended for European approval as a treatment for hemophilia, the company said Friday. The Danish pharmaceutical giant said European regulators have recommended ...

It is paramount to maintain a level of 100% of the replacement clotting factor for 2 weeks (preferably ... the biggest problem in patients with hemophilia. In hemophilia patients, it is very ...

Novo Nordisk's Alhemo (concizumab) receives a positive opinion from the EMA's CHMP for hemophilia A or B with inhibitors. The ...

Novo Nordisk’s Alhemo® (concizumab) has been recommended for approval by the European Medicines Agency's (EMA) Committee for ...